Healthcare Industry News:  DUSA Pharmaceuticals 

Biopharmaceuticals Personnel

 News Release - June 15, 2006

DUSA Pharmaceuticals Announces Election of Robert F. Doman to Board of Directors

WILMINGTON, MASSACHUSETTS--(Healthcare Sales & Marketing Network)--Jun 15, 2006 -- DUSA Pharmaceuticals, Inc. (NasdaqNM:DUSA ) announced today at the company's Annual Meeting of Shareholders that Robert F. Doman was elected to its Board of Directors. All of the other members of the Board were re-elected.

"Since joining DUSA as President and Chief Operating Officer in January of 2005, Bob has demonstrated the expertise necessary to lead DUSA's day-to-day operations and provide strategic thinking and guidance to the entire management team. Bob's nomination and election reflects both the Board's and shareholder's confidence in the skills he has brought to the company," said Geoff Shulman, DUSA's Chairman and Chief Executive Officer.

Mr. Doman has more than 25 years of industry related experience, with domestic and international experience in general management, acquisitions/licensing, business development, sales, marketing and strategic planning.

From 2000 until 2004, Mr. Doman served as President of Leach Technology Group, the medical device division of Leach Holding Corporation, a privately owned company. From 1999 to 2000, he was President, Device Product Development, of West Pharmaceutical Services (NYSE:WST ), a manufacturer of systems and device components for parenterally administered medicines and drugs. Prior to joining West Pharmaceutical Services, he worked in various senior management positions at Bristol-Myers Squibb. During this time, he also had significant exposure to the field of dermatology. From 1976 until 1990, he worked for Critikon, Inc., a Johnson & Johnson company.

DUSA Pharmaceuticals, Inc. is an integrated dermatology specialty pharmaceutical company focused primarily on the development and marketing of its LevulanŽ Photodynamic Therapy (PDT) technology platform, and complementary dermatology products. Levulan PDT is currently approved for the treatment of pre-cancerous actinic keratoses, and is being developed for the treatment of acne and photodamage. DUSA's other dermatology products include NicomideŽ, and the AVARŽ line, resulting from its recent merger with Sirius Laboratories, Inc. These products target patients with acne and rosacea. DUSA is also developing certain internal indications of Levulan PDT. DUSA is based in Wilmington, MA.

Source: DUSA Pharmaceuticals

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.